ABCG2 Overexpression Contributes to Pevonedistat Resistance

Rishil J. Kathawala(St. John's University), Steffan T. Nawrocki(University of Arizona), Jennifer S. Carew(University of Arizona), Claudia M. Espitia(The University of Texas System), Shariful Islam(University of Arizona), Zhe‐Sheng Chen(New York College of Traditional Chinese Medicine), Yunkai Zhang(Naval Medical Research Command), Pranav Gupta(St. John's University), Trace M. Jones(University of Arizona)
Cancers
February 12, 2020
10.3390/cancers12020429
Cited by 16

Related Papers

Microbiota in health and diseases
|Signal Transduction and Targeted Therapy|2022|2.9k
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
|Blood|2007|485
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
|Cancer Letters|2008|426
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|385